137 related articles for article (PubMed ID: 10477163)
1. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.
Padrón JM; van Moorsel CJ; Bergman AM; Smitskamp-Wilms E; van der Wilt CL; Peters GJ
Anticancer Drugs; 1999 Jun; 10(5):445-52. PubMed ID: 10477163
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Guechev A; Smid K; Loves WJ; Vermorken JB; Postmus PE; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):407-15. PubMed ID: 9933029
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction between cisplatin and gemcitabine in vitro.
Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
[TBL] [Abstract][Full Text] [Related]
5. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
6. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
[TBL] [Abstract][Full Text] [Related]
7. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
Van Moorsel CJ; Smid K; Voorn DA; Bergman AM; Pinedo HM; Peters GJ
Int J Oncol; 2003 Jan; 22(1):201-7. PubMed ID: 12469205
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
van Moorsel CJ; Pinedo HM; Smid K; Comijn EM; Voorn DA; Veerman G; Lakerveld B; Van der Vijgh WJ; Giaccone G; Postmus PE; Peters GJ
Eur J Cancer; 2000 Dec; 36(18):2420-9. PubMed ID: 11094319
[TBL] [Abstract][Full Text] [Related]
9. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
Yang LY; Li L; Jiang H; Shen Y; Plunkett W
Clin Cancer Res; 2000 Mar; 6(3):773-81. PubMed ID: 10741696
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy studies with gemcitabine.
van Moorsel CJ; Veerman G; Bergman AM; Guechev A; Vermorken JB; Postmus PE; Peters GJ
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-17-S7-23. PubMed ID: 9194475
[TBL] [Abstract][Full Text] [Related]
11. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.
van Moorsel CJ; Pinedo HM; Veerman G; Vermorken JB; Postmus PE; Peters GJ
Eur J Cancer; 1999 May; 35(5):808-14. PubMed ID: 10505043
[TBL] [Abstract][Full Text] [Related]
12. Postconfluent multilayered cell line cultures for selective screening of gemcitabine.
Smitskamp-Wilms E; Pinedo HM; Veerman G; Ruiz van Haperen VW; Peters GJ
Eur J Cancer; 1998 May; 34(6):921-6. PubMed ID: 9797708
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
van Moorsel CJ; Kroep JR; Pinedo HM; Veerman G; Voorn DA; Postmus PE; Vermorken JB; van Groeningen CJ; van der Vijgh WJ; Peters GJ
Ann Oncol; 1999 Apr; 10(4):441-8. PubMed ID: 10370787
[TBL] [Abstract][Full Text] [Related]
14. In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.
Wouters A; Pauwels B; Lardon F; Pattyn GG; Lambrechts HA; Baay M; Meijnders P; Vermorken JB
BMC Cancer; 2010 Aug; 10():441. PubMed ID: 20723210
[TBL] [Abstract][Full Text] [Related]
15. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
[TBL] [Abstract][Full Text] [Related]
16. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines.
Theodossiou C; Cook JA; Fisher J; Teague D; Liebmann JE; Russo A; Mitchell JB
Int J Oncol; 1998 Apr; 12(4):825-32. PubMed ID: 9499442
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) combined with interferon in human renal cell carcinoma cell lines.
Rohde D; Hayn HK; Blatter J; Jakse G
Int J Oncol; 1998 Jun; 12(6):1361-6. PubMed ID: 9592200
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.
van Bree C; Castro Kreder N; Loves WJ; Franken NA; Peters GJ; Haveman J
Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):237-44. PubMed ID: 12182997
[TBL] [Abstract][Full Text] [Related]
19. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
20. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Bergman AM; Giaccone G; van Moorsel CJ; Mauritz R; Noordhuis P; Pinedo HM; Peters GJ
Eur J Cancer; 2000 Oct; 36(15):1974-83. PubMed ID: 11000580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
